Story perspectives

Trump Orders FDA Not to Enforce Peptide Compounding Rules

By Drooid · Oct 28, 2026 · How we work

Same facts. Different interpretations.

How coverage differs

Left

U.S. President Donald Trump, via Department of Health and Human Services, issued a policy directing the FDA not to enforce rules on pharmacies compounding six peptides.
Health Secretary Robert F. Kennedy Jr., a “big fan” of peptides, pushed the policy to allow compounding pharmacies to sell them and curb gray-market imports.
FDA scientists warned the untested peptides could cause allergic reactions, kidney damage, or tumor growth.

Center

U.S. President Donald Trump, via HHS, issued a policy directing the FDA not to enforce rules on pharmacies compounding six unapproved peptides.
Critics, Dr. Peter Lurie of the Center for Science in the Public Interest, said the policy was timed to sway voters before the election.
The policy was crafted with little FDA scientist input, despite safety concerns.
An HHS-selected panel of doctors, pharmacists, consultants voted to drop peptide restrictions.

Blindspot

Health Secretary Robert F. Kennedy Jr., who calls himself a “big fan” of peptides, urged that compounding pharmacies be allowed to sell the six unapproved peptides to curb gray-market imports, according to the left-leaning source.
Within this story's sources, this angle appears mainly in Left-leaning coverage and receives less attention in Center-leaning coverage.

1 of 3

Peptide Safety Risks

U.S. President Donald Trump, via Department of Health and Human Services, issued a policy directing the FDA not to enforce rules on pharmacies compounding six peptides.
Health Secretary Robert F. Kennedy Jr., a “big fan” of peptides, pushed the policy to allow compounding pharmacies to sell them and curb gray-market imports.
FDA scientists warned the untested peptides could cause allergic reactions, kidney damage, or tumor growth.

1 / 3